Publicacións en colaboración con investigadores/as de Thomas Jefferson University (1)

2017

  1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

    The Lancet HIV, Vol. 4, Núm. 11, pp. e486-e494